Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

Randomized, Double Blind, Placebo Controlled, Single IV Dose Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder

The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.

Inclusion Criteria:

• diagnosis of major depressive disorder consistent with DSM-IV-TR
• current episode greater than 8 weeks in duration
• Hamilton Depression score >/- 21
• less than 25% reduction in depression during current episode assessed by ATRQ

Exclusion Criteria:

• Axis diagnosis of other psychiatric disorders
• Experiencing hallucinations, delusions, other psychotic symptomatology
• ECT during current episode